De Motu Cordis Expands Global IP Portfolio
De Motu Cordis grows its IP portfolio to 28 patents, fortifying innovations in emergency medicine for anaphylaxis with their drug-device dry powder inhaler.
De Motu Cordis Founder and CMO, Professor John Fraser Awarded Order of Australia
JANUARY 26, 2025
De Motu Cordis would like to congratulate Professor John Fraser, who has been named as an Officer of the Order of Australia (AO).
Professor John Fraser, from UQ’s Institute for Molecular Bioscience, has been appointed an Officer of the Order of Australia (AO) for his distinguished service to medicine as an intensive care physician and surgeon, and to global critical care research.
Professor Fraser received his PhD from UQ in 2010 and is the Director of Intensive Care Unit at St Andrew’s War Memorial Hospital in Brisbane and Chief Medical Officer at De Motu Cordis.
He also founded the Critical Care Research Group (CCRG) two decades ago.
With a global network spanning more than 60 countries, CCRG is a world leader in developing technologies and interventions to improve outcomes for critically ill patients – encompassing clinical, pre-clinical and engineering research.
The group is based at Australia’s largest cardiac hospital, The Prince Charles Hospital, and investigates better ways to support patients with heart and lung failure.
His work includes refining a method of keeping a heart “alive” outside the body for 12 hours – increasing the availability of donors’ hearts, a revolutionary practice that has helped people around the world.
“I am equal parts humbled and honoured to receive this huge accolade from my adoptive homeland of Australia,” Professor Fraser said.
“It represents not just my efforts, but the efforts of my many mentors, collaborators and team members I have had the good fortune to work with and learn from.
“None of it would have been possible without the guidance of my parents nor the love and support of my 5 wonderful kids.”
Story from UQ community recognised in Australia Day honours – UQ News – The University of Queensland, Australia
About DMC
“DMC is a clinical stage pharma company.”
DMC was founded in Brisbane, Australia by Professor John Fraser, an Intensivist and groundbreaking clinician, researcher, and company founder. John is also founder of the Critical Care Research Group and is a co-founder of BIVACOR Pty Ltd. John co-founded the COVID-19 Critical Care Consortium that facilitated collecting over 35 million data points from ICU units worldwide and aided in the development of treatment pathways.
Since inception, DMC has raised over US $21m in Seed rounds primarily in Australia. The majority of funding to date have been secured via the Queensland Business Development Fund, high net worth individuals and Australian family offices. A Series A financing round is planned for H2 2025, which will ideally be anchored by a US based VC.
De Motu Cordis Founder and CMO, Professor John Fraser Awarded Order of Australia
De Motu Cordis CMO, Prof. John Fraser, awarded the Order of Australia for his contributions to medicine and critical care research.
De Motu Cordis (DMC) receives a letter of support from Food Allergy Research and Education (FARE)
On November 1, 2024, DMC received a formal letter of support from Food Allergy Research and Education (FARE), the largest nonprofit organisation in the U.S. committed to enhancing the quality of life and health for individuals with food allergies through innovative research, education, and advocacy.